Filtered By:
Infectious Disease: Tuberculosis

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 74884 results found since Jan 2013.

IJERPH, Vol. 18, Pages 10404: Knowledge, Beliefs, and Perceptions of TB and Its Treatment amongst TB Patients in the Limpopo Province, South Africa
aluleke Despite the implementation of global plans to end tuberculosis (TB), this disease remains a major cause of ill-health and is the second leading cause of death. In 2019, globally, an estimated 10.0 million people fell ill and about 1.4 million died of TB. During the same year, South Africa was among the eight countries with the highest tuberculosis burden, contributing to two-thirds of the world’s total. Due to the high burden of the human immunodeficiency virus (HIV) epidemic, TB in South Africa is a major public health problem. Limpopo is amongst the provinces that are hardest hit by TB and HIV in South Afri...
Source: International Journal of Environmental Research and Public Health - October 2, 2021 Category: Environmental Health Authors: Hulisani Matakanye Takalani Grace Tshitangano Jabu Tsakani Mabunda Thelmah Xavela Maluleke Tags: Article Source Type: research

New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more diffic...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Gu érin-Unresponsive Non-Muscle-Invasive Bladder Cancer
CHICAGO, April 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy (a novel investigational intravesical drug delivery system) and cetrelimab monotherapy (an investigational anti-PD-1 monoclonal antibody administered intravenously) in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC), who are ineligible for, or decline, radical cystectomy. The study demonstrated that 72.7 percent of patients treated wit...
Source: Johnson and Johnson - April 30, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Tuberculosis and Lung Cancer
Does tuberculosis increase the risk of lung cancer? How does a diagnosis of TB affect those living with lung cancer and why is lung cancer sometimes misdiagnosed as TB?
Source: About.com Lung Cancer - July 7, 2013 Category: Cancer & Oncology Authors: lungcancer.guide at about.com Tags: health Source Type: news

The Ballabgarh Health and Demographic Surveillance System (CRHSP-AIIMS)
The Ballabgarh Health and Demographic Surveillance System (HDSS), also known as the Comprehensive Rural Health Services Project (CRHSP) Ballabgarh, is located in north India and was established in 1961 to develop a model for rural health-care practice in India. In addition to demographic surveillance and community-based research, CRHSP Ballabgarh provides preventive, health-promotion, and curative services to its surrounding population. The population served by CRHSP Ballabgarh in 2011 was about 90 000. The system collects data for the entire population through fortnightly visits by health workers (HWs). The system’s...
Source: International Journal of Epidemiology - August 2, 2013 Category: Epidemiology Authors: Kant, S., Misra, P., Gupta, S., Goswami, K., Krishnan, A., Nongkynrih, B., Rai, S. K., Srivastava, R., Pandav, C. S. Tags: Health and Demographic Surveillance System Profiles Source Type: research

Patients infected by tuberculosis and human immunodeficiency virus facing their disease, their reactions to disease diagnosis and its implication about their families and communities, in Burkina Faso: a mixed focus group and cross sectional study
Patients facing tuberculosis (TB) and human immunodeficiency virus (HIV) infection receive particular care. Despite efforts in the care, misconceptions about TB and HIV still heavily impact patients, their fam...
Source: BMC Research Notes - July 29, 2016 Category: Research Authors: Zieml é Clément Méda, Télesphore Somé, Issiaka Sombié, Daouda Maré, Donald E. Morisky and Yi-Ming Arthur Chen Source Type: research

Status of tuberculosis ‐related stigma and associated factors: a cross‐sectional study in central China
ConclusionsTB‐related stigma was high among TB patients in China. Interventions concentrating on reducing TB patients’ stigma in China should focus on improving patients’ family function and patients’ knowledge about TB.This article is protected by copyright. All rights reserved.
Source: Tropical Medicine and International Health - November 25, 2017 Category: Tropical Medicine Authors: Xiaoxv Yin, Shijiao Yan, Yeqing Tong, Xin Peng, Tingting Yang, Zuxun Lu, Yanhong Gong Tags: Original Article Source Type: research

An ontology for factors affecting tuberculosis treatment adherence behavior in sub-Saharan Africa
Conclusion: The outcome of the study is a novel ontology-based approach for curating and structuring scientific knowledge of adherence behavior in patients with TB in SSA. The ontology takes an evidence-based approach by explicitly linking factors to published clinical studies. Factors are structured around five dimensions: factor type, type of effect, regional variation, cross-dependencies between factors, and treatment phase. The ontology is flexible and extendable and provides new insights into the nature of and interrelationship between factors that influence TB adherence. Keywords: tuberculosis, treatment adherence be...
Source: Patient Preference and Adherence - April 26, 2016 Category: Global & Universal Tags: Patient Preference and Adherence Source Type: research

Knowledge, Attitudes, and Practices Regarding Tuberculosis in Timor-Leste: Results From the Demographic and Health Survey 2016.
CONCLUSIONS: This study identified socio-demographic risk factors for deficiences in population-based TB knowledge in Timor-Leste; these findings should be considered when designing TB communication, prevention, and control strategies. PMID: 30971078 [PubMed - in process]
Source: Journal of Preventive Medicine and Public Health - April 13, 2019 Category: International Medicine & Public Health Tags: J Prev Med Public Health Source Type: research

Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson To Retire, Effective December 31, 2021
NEW BRUNSWICK, N.J. (October 12, 2021) – Johnson & Johnson (NYSE: JNJ) today announced that Paul Stoffels M.D., currently Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson, will retire from the Company effective December 31, 2021.As the Vice Chairman of the Executive Committee and Chief Scientific Officer, Dr. Stoffels spearheaded the company’s research and product pipeline leading teams across sectors to set the company-wide mandate to discover and develop transformational healthcare solutions. Under his leadership, Johnson & Johnson revitalized its innovation pipel...
Source: Johnson and Johnson - October 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

IJERPH, Vol. 20, Pages 4136: A Communication-Based Intervention Study for Reducing Stigma and Discrimination against Tuberculosis among Thai High-School Students
This study is quasi-experimental in nature and is conducted in two high schools (n = 216 students). The study adopts purposive and systematic sampling techniques to select schools and students. The experimental group received a communication program for three months, whereas the control group received no intervention. The study uses generalized estimating equations to assess the overall program between the experimental and control groups at baseline, intervention, and follow-up periods. The outcomes reveal that the communication program effectively reduced TB stigma (p-value < 0.05, CI = 4.962, −1....
Source: International Journal of Environmental Research and Public Health - February 25, 2023 Category: Environmental Health Authors: Saowaluk Moonsarn Yuthichai Kasetjaroen Anne-Marie Bettex-Baars Anuchit Phanumartwiwath Tags: Article Source Type: research

Tuberculosis of the Cuboid: A Case Report and Review of the Literature
Tuberculosis (TB) remains a major global health problem. According to a recent World Health Organization report, it ranks as the second leading cause of death from an infectious disease worldwide. According to the “UK Health Protection Agency Tuberculosis in the UK: 2012 Report,” 8963 cases were reported in the United Kingdom in 2011. London had the greatest proportion of cases in the United Kingdom and the greatest rate of disease. TB affecting the foot is rare, affecting about 10% of all skeletal TB cases.
Source: Journal of Foot and Ankle Surgery - June 15, 2014 Category: Orthopaedics Authors: Luckshmana Jeyaseelan, Daniel Williams, Saket Tibrewal, Syed Asif Ali, Mahmood Hassan, Krishna Vemulapalli Tags: Case Reports and Series Source Type: research

Buffered Qualitative Stability explains the robustness and evolvability of transcriptional networks
The gene regulatory network (GRN) is the central decision-making module of the cell. We have developed a theory called Buffered Qualitative Stability (BQS) based on the hypothesis that GRNs are organised so that they remain robust in the face of unpredictable environmental and evolutionary changes. BQS makes strong and diverse predictions about the network features that allow stable responses under arbitrary perturbations, including the random addition of new connections. We show that the GRNs of E. coli, M. tuberculosis, P. aeruginosa, yeast, mouse, and human all verify the predictions of BQS. BQS explains many of the sma...
Source: eLife - September 2, 2014 Category: Biomedical Science Authors: Albergante, L., Blow, J. J., Newman, T. J. Tags: Human biology and medicine Source Type: research

Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials.
Authors: Xu Z, Xu P, Fan W, Yang G, Wang J, Cheng Q, Yu M Abstract Antitumor necrosis factor (TNF) agents have been widely used for the treatment of spondyloarthritis (SpA) and ankylosing spondylitis (AS). However, these agents may increase the risk of infection due to suppressing the immune response. The present meta-analysis was performed to systematically investigate the risk of overall infection, serious infection and tuberculosis in patients with SpA and AS treated with anti-TNF agents. Medline, Embase and the Cochrane library were searched for randomized controlled trials (RCTs) published between January 1998...
Source: Experimental and Therapeutic Medicine - October 19, 2017 Category: General Medicine Tags: Exp Ther Med Source Type: research